Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:EQ NASDAQ:INDP NASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.18-6.3%$1.18$0.95▼$1.95$37.02M-0.11151,245 shs93,841 shsEQEquillium$3.08+6.2%$2.13$0.27▼$3.12$183.36M1.77398,702 shs4.58 million shsINDPIndaptus Therapeutics$1.92+9.1%$2.05$0.92▼$19.91$199.31M1.2597,076 shs138,189 shsSPRBSpruce Biosciences$50.70-1.1%$59.11$4.35▼$240.00$141.11M3.1245,526 shs31,189 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals0.00%+6.78%+13.51%+10.53%-18.18%EQEquillium0.00%+28.32%+42.16%+51.04%+705.78%INDPIndaptus Therapeutics0.00%+44.26%-37.14%-16.19%-81.33%SPRBSpruce Biosciences0.00%+0.37%-10.55%-5.42%+879.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.18-6.3%$1.18$0.95▼$1.95$37.02M-0.11151,245 shs93,841 shsEQEquillium$3.08+6.2%$2.13$0.27▼$3.12$183.36M1.77398,702 shs4.58 million shsINDPIndaptus Therapeutics$1.92+9.1%$2.05$0.92▼$19.91$199.31M1.2597,076 shs138,189 shsSPRBSpruce Biosciences$50.70-1.1%$59.11$4.35▼$240.00$141.11M3.1245,526 shs31,189 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals0.00%+6.78%+13.51%+10.53%-18.18%EQEquillium0.00%+28.32%+42.16%+51.04%+705.78%INDPIndaptus Therapeutics0.00%+44.26%-37.14%-16.19%-81.33%SPRBSpruce Biosciences0.00%+0.37%-10.55%-5.42%+879.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 3.00Buy$4.50281.36% UpsideEQEquillium 2.78Moderate Buy$7.57145.83% UpsideINDPIndaptus Therapeutics 1.00SellN/AN/ASPRBSpruce Biosciences 2.50Moderate Buy$176.60248.32% UpsideCurrent Analyst Ratings BreakdownLatest ATNM, EQ, SPRB, and INDP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026SPRBSpruce Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$200.00 ➝ $150.005/28/2026EQEquillium Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$7.005/28/2026EQEquillium Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.005/28/2026EQEquillium Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/28/2026EQEquillium Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$1.00 ➝ $6.005/27/2026SPRBSpruce Biosciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/14/2026SPRBSpruce Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$170.00 ➝ $150.004/27/2026SPRBSpruce Biosciences Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$140.004/23/2026EQEquillium OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.004/21/2026INDPIndaptus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026EQEquillium Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium Pharmaceuticals$90K411.36N/AN/A$1.31 per share0.90EQEquillium$41.10M4.74N/AN/A$0.47 per share6.55INDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/ASPRBSpruce Biosciences$4.91M28.40N/AN/A$39.72 per share1.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$0.75N/AN/AN/AN/A-100.85%-47.89%N/AEQEquillium-$22.40M-$0.32N/AN/AN/AN/A-61.43%-53.72%8/13/2026 (Estimated)INDPIndaptus Therapeutics-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)SPRBSpruce Biosciences-$38.97M-$36.60N/AN/AN/AN/A-155.40%-101.67%8/13/2026 (Estimated)Latest ATNM, EQ, SPRB, and INDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026INDPIndaptus Therapeutics-$1.87-$0.23+$1.64-$0.23N/AN/A5/13/2026Q1 2026EQEquillium-$0.04-$0.06-$0.02-$0.06N/AN/A5/13/2026Q1 2026SPRBSpruce Biosciences-$7.9340-$8.94-$1.0060-$8.94N/AN/A3/25/2026Q4 2025EQEquillium-$0.07-$0.04+$0.03-$0.04N/AN/A3/17/2026Q4 2025INDPIndaptus Therapeutics-$4.36-$3.10+$1.26-$3.10N/AN/A3/12/2026Q4 2025SPRBSpruce Biosciences-$9.1575-$9.58-$0.4225-$9.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25EQEquilliumN/A18.6218.62INDPIndaptus TherapeuticsN/A2.342.34SPRBSpruce Biosciences0.164.674.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%EQEquillium27.05%INDPIndaptus Therapeutics7.06%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals0.60%EQEquillium17.84%INDPIndaptus Therapeutics23.60%SPRBSpruce Biosciences4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.38 million29.32 millionOptionableEQEquillium4063.23 million51.95 millionNot OptionableINDPIndaptus Therapeutics6113.24 million86.52 millionNot OptionableSPRBSpruce Biosciences202.75 million2.63 millionOptionableATNM, EQ, SPRB, and INDP HeadlinesRecent News About These CompaniesSpruce Biosciences Announces Data Presentation at the 18th International MPS SymposiumMay 28, 2026 | businesswire.comSpruce Biosciences to Participate in Upcoming Conferences in JuneMay 27, 2026 | businesswire.comSpruce Biosciences Stockholders Approve Directors and Annual Say-on-PayMay 26, 2026 | tipranks.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Receives $186.60 Average Target Price from AnalystsMay 21, 2026 | americanbankingnews.comSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13, 2026 | businesswire.comSpruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President ...May 4, 2026 | bakersfield.comBCraig-Hallum initiates coverage of Spruce Biosciences (SPRB) with buy recommendationApril 28, 2026 | msn.comWhy is Spruce Biosciences stock sinking Tuesday?April 21, 2026 | msn.comSpruce Biosciences prices $60M public offering at $50.00 per shareApril 21, 2026 | msn.comSpruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | businesswire.comSpruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | finance.yahoo.comWall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to TradeApril 3, 2026 | zacks.comDoes Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?March 18, 2026 | zacks.comSpruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net LossMarch 17, 2026 | insidermonkey.comSpruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial OfficerMarch 9, 2026 | pharmiweb.comPSpruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate UpdatesMarch 9, 2026 | businesswire.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | insidermonkey.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | msn.comSpruce Biosciences to Present at Upcoming Investor Conferences in MarchMarch 2, 2026 | businesswire.comSPRB stock drops after company pushes back application submission timeline for experimental Sanfilippo syndrome therapyFebruary 18, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesFrom High-Yield to High-Growth: 3 Stocks Boosting DividendsBy Leo Miller | May 18, 2026Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIABy Jeffrey Neal Johnson | May 21, 2026Why OpenAI’s IPO Plans Could Be a Massive Win for MicrosoftBy Chris Markoch | May 13, 2026A Deep Dive Into NVIDIA’s Latest Portfolio MovesBy Leo Miller | May 19, 2026Amazon vs. Alibaba: One Is Clearly The Better Value Play right NowBy Sam Quirke | May 14, 2026ATNM, EQ, SPRB, and INDP Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.18 -0.08 (-6.35%) Closing price 04:00 PM EasternExtended Trading$1.17 -0.01 (-0.68%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Equillium NASDAQ:EQ$3.08 +0.18 (+6.21%) Closing price 04:00 PM EasternExtended Trading$2.88 -0.20 (-6.49%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Indaptus Therapeutics NASDAQ:INDP$1.92 +0.16 (+9.09%) Closing price 04:00 PM EasternExtended Trading$1.81 -0.11 (-5.73%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Spruce Biosciences NASDAQ:SPRB$50.70 -0.57 (-1.11%) Closing price 04:00 PM EasternExtended Trading$50.92 +0.22 (+0.44%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
